A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 22 Aug 2023
At a glance
- Drugs MRNA 2736 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Moderna Therapeutics
Most Recent Events
- 15 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Jul 2023 Planned initiation date changed from 12 Jul 2023 to 15 Aug 2023.
- 03 Jul 2023 New trial record